Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Velcade® in IgA Nephropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years of age or older.~2. Must have IgA nephropathy documented by kidney biopsy.~3. Must have greater than 1gm of proteinuria a day.~4. Must be on a stable dose of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blocking agent (ARB) for at least 4 weeks prior to screening.~Exclusion Criteria:~1. Low platelet count and neutrophil count within certain limits defined for enrollment.~2. Underlying peripheral neuropathy.~3. Having cardiac problems, such as myocardial infarction, heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~4. Allergic to VELCADE®, boron or mannitol.~5. Female subjects who are pregnant or breast-feeding.~6. Recent use of investigational drug within 14 days before enrollment.~7. Having serious medical conditions and infections (including HIV,or hepatitis B or C) or psychiatric illness likely to interfere with participation in the study.~8. Diagnosed or treated for cancer within 3 years of participation in the study, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, and in situ malignancy, or low-risk prostate cancer after curative therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Velcade® therapy (Type: EXPERIMENTAL): Patients with greater than 1gm of proteinuria per day will receive Velcade®.

Based on this trial design, predict the completion outcome and termination type (if applicable).